Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Citi
Queensland Health
Cipla
Colorcon
Moodys
Medtronic
Covington
McKinsey

Generated: June 24, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: olmesartan medoxomil

« Back to Dashboard

olmesartan medoxomil Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Amneal Pharms Co olmesartan medoxomil 207480 5MG TABLET;ORAL
Sciegen Pharms Inc olmesartan medoxomil 208130 20MG TABLET;ORAL
Sciegen Pharms Inc olmesartan medoxomil 208130 5MG TABLET;ORAL
Glenmark Pharms Ltd olmesartan medoxomil 203281 5MG TABLET;ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKinsey
Fish and Richardson
Moodys
Accenture
Cipla
McKesson
Boehringer Ingelheim
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.